Robert Jan Lebbink

Associate Professor

Strategic program(s):

Contact

The purinergic receptor P2X7 as a modulator of viral vector-mediated antigen cross-presentation Ylenia Longo, Sara Moreno Mascaraque, Giuseppe Andreacchio, Julia Werner, Ichiro Katahira, Elena De Marchi, Anna Pegoraro, Robert Jan Lebbink, Karl Köhrer, Patrick Petzsch, Ronny Tao, Francesco Di Virgilio, Elena Adinolfi, Ingo Drexler
Frontiers in Immunology, 2024, vol. 15

Proinsulin degradation and presentation of a proinsulin B-chain autoantigen involves ER-associated protein degradation (ERAD)-enzyme UBE2G2 Tom Cremer, Hanneke Hoelen, Michael L van de Weijer, George M Janssen, Ana I Costa, Peter A van Veelen, Robert Jan Lebbink, Emmanuel J H J Wiertz
PLoS ONE, 2024, vol. 19

Reactivation of Multidrug-Resistant HSV-1 in a Post-Allogenic Hematopoietic Stem Cell Transplant Patient Shuxuan Zheng, Lidewij L.W. Rümke, Bruno Tello Rubio, Malbert R.C. Rogers, Geerte L. Van Sluis, Jürgen H.E. Kuball, Annelies Riezebos-Brilman, Robert Jan Lebbink, Frans M. Verduyn Lunel
Open Forum Infectious Diseases, 2024, vol. 11

m⁶A Reader YTHDC1 Impairs Respiratory Syncytial Virus Infection by Downregulating Membrane CX3CR1 Expression Lucas W. Picavet, Ellen C.N. van Vroonhoven, Rianne C. Scholman, Yesper T.H. Smits, Rupa Banerjee, Sjanna B. Besteman, Mattheus C. Viveen, Michiel M. van der Vlist, Marvin E. Tanenbaum, Robert J. Lebbink, Sebastiaan J. Vastert, Jorg van Loosdregt
Viruses, 2024, vol. 16

Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice Akashdip Singh, Eline T A M Mommers-Elshof, Saskia V Vijver, J H Marco Jansen, Susanne Gonder, Robert Jan Lebbink, Dominique Bihan, Richard W Farndale, Louis Boon, Solomon Langermann, Jeanette H W Leusen, Dallas Flies, Linde Meyaard, M Ines Pascoal Ramos
Cancer Immunology, Immunotherapy, 2024, vol. 73

CRISPR/Cas9-mediated genome editing of the thymidine kinase gene in a clinical HSV-1 isolate identifies F289S as novel acyclovir-resistant mutation Shuxuan Zheng, Georges M.G.M. Verjans, Anouk Evers, Ellen van den Wittenboer, Jeroen H.T. Tjhie, Robert Snoeck, Emmanuel J.H.J. Wiertz, Graciela Andrei, Jeroen J.A. van Kampen, Robert Jan Lebbink
Antiviral Research, 2024, vol. 228

2001: The role of LAIR-1 engagement by Ep-CAM in tolerance and tumor immunity